References
- Ostadkarampour M, Eklund A, Moller D, Glader P, Olgart Höglund C, Lindén A, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren’s syndrome. Clin Exp Immunol 2014;178:342–52.
- James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol 2018;11:677–87.
- Garcia-Montoya L, Marzo-Ortega H. The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Ther Adv Musculoskelet Dis 2018;10:169–80.
- Tan HL, Rosenthal M. IL-17 in lung disease: friend or foe? Thorax 2013;68:788–90.
- Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL17A expression in the granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) 2012;51:37–46.
- Ramstein J, Broos C, Simpson L, Ansel K, Sun S, Ho M, et al. IFN-g–producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med 2016;193:1281–91.
- Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like eeaction in a patient with psoriasis. Clin Exp Dermatol 2020;45:455–6.
- Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis. Clin Exp Rheumatol 2019;37:344–5.
- Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693–700.
- Nyckowski T, Ceilley R, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. J Cutaneous Med 2017;2:95–8.